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Abstract
Type 2 diabetes mellitus accounts for ≈90–95% of those with diabetes, about
50% of those with type 2 diabetes are unaware and it can remain undiagnosed for up
to 12 years, ≥25% of people have evidence of microvascular complications at diag-
nosis. The consequences of diabetes can be reduced by screening and early inter-
ventions. Urinalysis as a screening test is limited by its low sensitivity ranging from
21% and 64%, though has high specificity (>98%), it has a place where no other
procedure is available. Fasting plasma glucose though recommended as a universal
screening and diagnostic test for diabetes mellitus, a changed in the diagnostic
criteria was made when this did not give corresponding hyperglycaemic impact
compared to the OGTT results, bringing a complex and variable effect on the
prevalence of diabetes and on subjects diagnosed. To date the searching to finding
the corresponding FPG to what is normal or IGT is still ongoing. FPG testing poorly
identify early signs of dysglycaemia. This is due to the difficulty ensuring compli-
ance with instructions about fasting, FPG represents glucose handling during the
moment of fasting period only and is affected easily by short-term lifestyle changes,
FPG has diurnal variation, higher in the morning than in the afternoon, these may
cause serious misclassifications. OGTT do indicates the pathophysiology responsible
for diabetes better as it provides information on what happens in the postprandial
state when the functional capacity of pancreatic β-cell is crucial. It accurately
detects changes in post-prandial glycaemia that tend to precede changes in fasting
glucose. OGTT is the gold standard for the diagnosis of GDM and the only means of
identifying people with IGT and WHO placed emphasis on the OGTT as the “gold
standard”, in diagnosis of dysglycaemia. Reproducibility can be improved remark-
ably when patient preparation, a forvarable atmosphere during the procedure,
standardized sampling protocol, sample handling, and analysis are given high
attention. Measurement of A1c equals the assessment of hundreds of FPG levels and
also captures postprandial glucose peaks. Regrettably, it has been shown that 44%
of people with newly diagnosed diabetes with OGTT had A1c <6.0% and that a
stronger correlations with plasma glucose is better in subjects with known diabetes,
but not in the general population. A1C values just above the upper limits of normal
require OGTT to be correctly interpreted; it is not available in many part of the
world. Finally, A1c can not diagnose IFG and IGT to disclose high-risk subjects for
1
diabetes. In conclusion an OGTT is undeniably the best test in investigation of
dysglycaemia, either with the intention of testing for pre-diabetes, type 2 diabetes,
or for gestational diabetes mellitus.
Keywords: Dysglycaemia, T2DM, GDM, Screening, Urinalysis,
Fasting Plasma Glucose, OGTT, A1c
1. Introduction
The term diabetes mellitus describes a metabolic disorder of multiple aetiology
characterised by chronic hyperglycaemia with disturbances of carbohydrate, fat
and protein metabolism resulting from defects in insulin secretion, insulin action, or
both.
The diabetes epidemic is accelerating in the developing world and Type 2 diabe-
tes has been recently reported in children and adolescents [1]. This is likely to
increase further the burden of chronic diabetic complications worldwide. Diabetes
is associated with reduced life expectancy, significant morbidity due to specific
diabetes related microvascular complications, increased risk of macrovascular com-
plications (ischaemic heart disease, stroke and peripheral vascular disease), and
diminished quality of life. These can be reduced by screening and early interven-
tions (prevention or treatment).
2. Classification of diabetes mellitus
Several distinct types of diabetes mellitus exist and are caused by a complex
interaction of genetic and environmental factors, however, assigning a type of diabe-
tes to an individual often depends on the circumstances present at the time of
diagnosis, and many diabetic individuals do not easily fit into a single class. Therefore
understanding the pathogenesis of the hyperglycaemia and to treat it effectively is
more important. It can therefore simply be classified as presented below [2–4].
Type 1 diabetes (β-cell destruction, either immune-mediated or Idiopathic),
accounts for only 5–10% of those with diabetes mellitus, usually leading to absolute
insulin deficiency. The immune-mediated has strong HLA associations, linkage to
DQA and DQB genes and is influence by DRB genes, while the idiopathic has no
known aetiology, have permanent insulinopaenia, prone to ketoacidosis, has no
evidence of autoimmunity, strongly inherited and is not HLA associated.
Type 2 diabetes (ranging from predominantly insulin resistance with relative
insulin deficiency to predominantly an insulin secretory defect with insulin resis-
tance), accounts for ≈90–95% of those with diabetes, and most patients are obese
and/or have an increased percentage of body fat with predominant abdominal
region distribution, ketoacidosis seldom occurs spontaneously. Patients may have
normal or elevated insulin levels, though still less with respect to degree of
hyperglycaemia, thus insulin secretion is defective and insufficient to compensate
for insulin resistance. This type of diabetes is frequently associated with a high
genetic predilection compared to the autoimmune form of type 1 diabetes, yet the
genetics are complex and not obviously defined.
Gestational diabetes mellitus (GDM) [4]: Defined as any magnitude of glu-
cose intolerance with onset or first recognition during pregnancy, whatever modal-
ities of treatment use or whether the condition lingers after index pregnancy. It
include unrecognized glucose intolerance antedating or begun in the index preg-
nancy. It complicates ≈4% of all pregnancies in the USA, with prevalence ranging
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from 1 to 14% of pregnancies, depending on the population studied. GDM repre-
sents nearly 90% of all pregnancies complicated by diabetes. Deterioration of glu-
cose tolerance occurs normally during pregnancy, particularly in the 3rd trimester.
Other specific types of diabetes [4]:
a. Genetic defects of the β-cell: Fair numbers of diabetes are affiliated with
monogenetic defect in β-cell function, referred to maturity onset diabetes of
the young (MODY) and are characterised by impaired insulin secretion with
minimal or no defects in insulin action. Inherited in an autosomal dominant
pattern
b. Genetic defects in insulin action: These are rare causes of diabetes sequel to
genetic abnormalities of insulin action. The metabolic flaws amalgamated
with mutations of the insulin receptor may traverse from hyperinsulinaemia
and modest hyperglycaemia to severe diabetes and some may have acanthosis
nigricans, women may be virilized and have enlarged, cystic ovaries.
Leprechaunism and Rabson-Mendenhall syndromes are two paediatric
syndrome with mutations in the insulin receptor gene
c. Diseases of the exocrine pancreas: Any process that diffusely injures the
panaceas can causes diabetes, ranging from infections, trauma, metabolic,
and rarely neoplasm
d. Endocrinopathies: Several hormones (growth hormone, cortisol, glucagon,
epinephrine) antagonize insulin action. Excess amounts of these hormones as
noted in acromegaly, Cushing’s syndrome, glucagonoma,
Phaeochromocytoma, respectively can cause diabetes
e. Drugs or chemical-induced diabetes: Many drugs can impair insulin
secretion. These drugs may not cause diabetes by themselves but they may
precipitate diabetes in individuals with insulin resistance
f. Infections: Certain viruses have been associated with β-cell destruction; eg.
Congenital rubella, Coxsackievirus B, cytomegalovirus, adenovirus, and
mumps have been implicated in inducing certain cases of the diabetes
g. Unknown forms of immune-mediated diabetes: In this variety, two
conditions are known, others may occur. The stiff-man syndrome
distinguished by inflexible axial muscles with painful spasms. Patients
routinely present with high titers of the GAD autoantibodies, and roughly
one-third will develop diabetes
h. Other genetic syndromes sometimes associated with diabetes:Many genetic
syndromes are accompanied by an increased incidence of diabetes mellitus, eg.,
Down’s syndrome, Klinefelter’s syndrome, and Turner’s syndrome. Wolfram’s
syndrome is an autosomal recessive disorder characterised by insulin-deficient
diabetes and the absence of β-cells at autopsy
Prevalence and burden of diabetes mellitus, Table 1.
Diabetes burden goes beyond individual but extends to families and society as a
whole. It has huge consequences affecting both national productivity and econo-
mies particularly in the low- and middle-income countries when considering the
projection for the year 2025.
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Determinates of increasing prevalence of diabetes mellitus may be summarized
as: Rising levels of overweight/obesity; increasing age of life expectancy in the
general population; decreasing age of onset of type 2 diabetes; increasing number
diagnosed due to decreased level of fasting plasma glucose; improved methods of
health records; and increasing number of detection by practice-based screening and
greater public awareness.
3. Need for screening for dysglycaemia
About 50% of those who have diabetes are unaware since the most prevalent
form [9], Type 2 diabetes, can remain undiagnosed for many years, up 12 years
[10], ≥25% of people have evidence of microvascular complications at diagnosis
[11–13] and individuals with undiagnosed T2DM are at significantly higher risk for
macrovascular complications than the nondiabetic population. Therefore, the mag-
nitude of the epidemic increase in diabetes, particularly among younger age group
including children, its serious long-term consequences, the high prevalence of
undiagnosed diabetes and the proportion of cases with evidence of complications at
diagnosis, coupled with complex treatment requirements that are difficult and
costly to implement, undoubtedly create a strong imperative for screening, making
the prevention of diabetes a critical public health goals. Since 1997 some major
clinical trials examined whether lifestyle changes or pharmacologic interventions
would prevent or delay the development of diabetes in populations at high risk
[14–16]. These trials achieved 25–60% reduction in development of diabetes and the
largest reduction by lifestyle modification and thiazolidinediones [14–16], though a
lesser reduction (25—30%) were achieved with other drugs [16]. These must be
emphasized particularly in the developing countries where the expected increase is
disproportionately higher.
3.1 Considerations in screening of a disease in general
The term screening should be based on the WHO principles of screening docu-
ment [17]. Screening is offered to individuals at sufficiently high risk of a particular
disorder to be informed for further directives. These are usually carried out on
a. The prevalence is increasing and is projected to reach pandemic proportions over the next 10–
20 years.
b. By the year 2025, diabetes population will reach 333 million 90% will have Type 2 diabetes.
c. There will be disproportionate in the developed and developing countries, 42% (increase from
51 to 72 million) and 170% (increase from 84 to 228 million), respectively
d. Thus, >75% of all people with diabetes will be in the developing countries, as compared to 62%
in 1995, over a period 30 years
e. Without interventions to halt the increase in diabetes, there will be at least 629 million people
living with diabetes by 2045.
f. In most Western societies, the overall prevalence has reached 4–6%, and is as high as 10–12%
among 60–70-year-old people.
g. High blood glucose causes almost 4 million deaths each year, and the IDF estimates that the
annual global health care spending on diabetes among adults was US$ 850 billion in 2017.
h. The annual health costs caused by diabetes and its complications account for around 6–12% of
all health-care expenditure.
i. The ADA estimated the national costs of diabetes in the USA for 2002 to be $US 132 billion,
increasing to $US 192 billion in 2020.
Table 1.
The BURDEN of Diabetes Mellitus [5–8].
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asymptomatic individual and are often initiated by medical personnel or authorities.
Screening will not only benefit the individual but the society at large.
Although it is desirable to have a test that is both highly sensitive and highly
specific, this is usually not possible. Only a valid, reliable and reproducible test in a
population is recommended. This requires uniform procedures and methods, stan-
dardized techniques, properly functioning equipments, well trained personnel, and
quality assurances are necessary to achieve these properties. Screening for
dysglycaemia requires three-stages: (a) selection from the general population using
practice registers or self-completed questionnaires amongst at high risk; (b) Testing
blood glucose, eg OGTT; and (c) confirmation (or not) of raised blood glucose
noted in stage (b) above using the same method of glucose testing. The biochemical
tests currently available are blood glucose (Fasting blood glucose or OGTT), blood
HbA1c or blood fructosamine measurements or urine glucose measurements. Each
screening test needs a designated and pre-determined threshold or “cut point” that
defines high risk.
WHO adapted 10 criteria that still serve as foundation for much of the discus-
sions surrounding screening programs and are as indicated in Table 2 [17].
The above criteria is not focus on the test itself but the disease and every
criterion should be present for a given screening test to improve the health of the
population.
3.2 Applying these qualities to dysglycaemia screening
The main reasons for the current interest in screening for T2DM can be sum-
marized as follows [18]; which undauntedly fulfills the WHO principles of screen-
ing” document [17]
a. Type 2 diabetes is becoming more common and many with the condition,
about ≥30%, are undiagnosed [19]
b. The rising prevalence of T2DM world-wide [18], the seriousness of the
immediate effects and long-term complications of T2DM are alarming
c. That there is a long, latent, asymptomatic period in which the condition can
be detected [20]
d. Many of newly referred cases of T2DM already have evidence of the
microvascular complications of diabetes
a. The prevalence of disease to be screened for must
be high in that particularly population to increase
sensitivity of the test
b. There must be an acceptable treatment for
patient with the disease
c. Methods for diagnosis and treatment should not
only be available but affordable
d There must be a recognized latent or early
symptomatic period
e. There should be a suitable test or otherwise
that is acceptable to the population
f. The natural history of the disease should be
adequately understood
g. There should be an agreed policy on whom to
screen and treat as a patient
h. The cost of case-finding should be
economically balance with attended objective
of treatment
i. Screening should be a continuous process for
that particular population
Table 2.
The following criteria should available for disease to qualify for screening [17].
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e. There have been advances in risk scoring, screening methods and more
convenient methods of blood testing using HbA1c in non-fasting state
f. Diabetes care is advanced, including screening for detection of complications
early enough and a wider range of treatments for glycaemia and its
complications
g. Evidence supporting the efficacy of intensive blood glucose control [20, 21],
blood pressure control [22], blood lipid control [23], and these development
of CVD in T2DM
h. Increasing pressure from professional organisations, lay groups and from
some of the members associations of IDF to institute screening for type 2
diabetes if only to further highlight the increasing prevalence and public
health importance of the condition
i. Individuals with IGT have increased risk of CVD and on average, 11% of
people with pre-diabetes develop type 2 DM each yr. (1.5–4%) and in 10 yrs.
and 50% higher risk of CVD, this can be prevented or delayed by Life style
and/or pharmacologic interventions.
3.3 However not everybody is convinced that it is worthwhile screening for
type 2 DM and their views are
a. Some of the NSC criteria for screening programme are not met [18]
b. A 13-year follow-up in health measures or cardiovascular morbidity showed
no advantage after screening for diabetes
c. The ADDITION trial did not show any benefit after applying intensified
management
d. Up to now there is yet to be a perfect screening test for dysglycaemia
e. If other cardiovascular risk factors are assessed and addressed, the benefits of
screening for hyperglycaemia are modest in terms of further reducing
cardiovascular risk
f. The proportion of undiagnosed diabetes has probably been reduced by
opportunistic screening
Although there are advances in screening for and treatment of type 2 diabetes,
the policies and practices do have profound consequences for individuals, health
systems and society in general [18].
3.4 Consequences for individuals’ include
a. The time and other resources necessary to undergo the screening and
diagnostic tests may not be there particularly for the poor [18]
b. The fair of unknown on both the test outcome, the reflection on societal
views, the cost of treatment and what is said about the disease in the society is
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grave. These may include occupational discrimination and/or increased costs
or difficulty in obtaining insurance
3.5 The consequences on the health system and society as a whole are
1.The costs and other consequences particularly on primary health care system
of carrying out screening and confirmatory test may be huge and unattainable
[18]
2.The additional costs of starting treatment early of diabetes and preventions
and/or its complication
3.Since there is no perfect screening test yet, consequences of false negative and
false positive results are inevitable and is grave
4.Any loss of production as a result of the earlier diagnosis of the condition(from
absence from work or reduced job opportunities, for example)
3.6 The potential benefits of early detection of T2DM are
a. Not only boost life span but also the quality resulting from a diminish severity
and occurrence of instantaneous effects or prevention or slow diabetes long-
term complications [18]
b. Increase savings and allow redistribution by reduced levels of care required for
diabetes complications (reduction in hospital admissions and length of stay)
4. Methods use for screening of dysglycaemia
4.1 Urinalysis
The usefulness of urinary glucose as a screening test is limited because of the low
sensitivity ranging from 21% and 64% with specificity >98% in studies which
included performing OGTT in the entire study population or a random sample of
negative screeners. Despite this, urine glucose testing may have a place in low
resource settings where no other procedure is available. This is particularly so when
the prevalence of undiagnosed diabetes is likely to be high [23, 24]. Urine should be
protected from direct sunlight, add 5 ml glacial acetic acid to preserve glucose in the
urine otherwise up to 40% may be lose after 24-hr storage at room temperature
[25]. Keeping samples on ice-water slurring during collection is also recommended
[26]. However, this may not be feasible in rural areas of developing countries; it is
therefore recommended that urinalysis should be done immediate after urine
collection in such situations.
4.2 Blood glucose estimation
Plasma glucose estimation has high intraindividual biological variability (4–
14%). This is accounted for by method of sample collection and storage, lifestyle
measures while preparing for sample collection like exercise, calorie restriction and
difficulty in ensuring fasting state. About 3-8 mg/dl/hr. of glucose is lose in a sample
kept at room temperature. Therefore, in interpreting blood glucose test result, the
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need to be conversant with causes of intraindividual and interindividual variation of
blood glucose is necessary. Such variability can be grouped as
a. The biological variability is substantially greater than analytical variability
b. Analytical imprecision <3.3%
c. Bias <2.5%
d. Total error < 7.9%
e. Glucose assay 4%
f. Biological CV 6.9%
On the basis of biological variation, glucose analysis having analytical impreci-
sion 3.3%, bias 2.5%, and total error 7.9%, may produce classification errors,
although imprecision is usually low at the diagnostic decision limits. It is also
believed generally that glucose assay is highly reproducible across laboratories,
however, a recent survey conducted in 6,000 US laboratories clearly documented a
significant bias in glucose assessment in as many as 41% of them, yielding a
misclassification of glucose tolerance in 12% of subjects [27]. The coefficients of
variation of A1c, FPG, and 2-h PG were demonstrated to be 3.6%, 5.7%, and 16.6%
respectively [28], reflecting both biological and analytical variability.
Preanalytical processing of blood samples can markedly affect the results of
plasma glucose readings because ongoing glycolysis by erythrocytes and leukocytes
prior to centrifugation lowers its concentration [29, 30]. A study reported 5–7%
[0.6 mmol/L (10 mg/dl)] an average rate of glycolysis per hour [31]. This varies
with the glucose concentration, temperature, white blood cell count and other
factors [32], for example, it has been estimated that pre-analytical variability of FPG
is 5–10% and the within day-day variability is 12–15%. Glycolysis can be attenuated
by inhibition of enolase with sodium fluoride (2.5 mg fluoride/ml of blood) or, less
commonly, lithium iodoacetate (0.5 mg/ml of blood). A citrate tubes should be use
if a delay in centrifugation is expected because citrate more rapidly inhibits glycol-
ysis [30]. It should be noted that although fluoride maintains long-term glucose
stability, the rates of decline of glucose in the first hour after sample collection in
tubes with and without fluoride are virtually identical [31]. Currently, both WHO
and ADA recommend that for preanalytical processing for plasma glucose mea-
surements involves venous blood collection into sodium fluoride (NaF) tubes with
placement in ice-water slurry prior to centrifugation within 30 min of sample
collection [33, 34]. The benefit of this policy is demonstrated in the following
studies: An observed increase rate of GDM from 11.6% to 20.6% on changing to a
protocol of centrifuging blood collected into NaF tubes within 10 min of venipunc-
ture compared to delayed centrifugation was noted [35]. A study in Ireland showed
a 2.7-fold higher (38.1% compared with 14.2%) when the ADA preanalytic protocol
was followed compared with the previous standard practice of collecting blood into
NaF tubes, leaving them at room temperature, and centrifuging after collection of
all three samples [36]. Similarly, the impact of long delays in centrifugation for
OGTT samples collected in NaF tubes on GDM diagnosis in Western Australia was
estimated to be an under diagnosis rate of 62% [37]. In HAPO, a reference study for
GDM, blood samples for all glucose measurements were collected into NaF tubes,
placed in ice-water slurry immediately after phlebotomy, and kept that way until
they could be centrifuge and separated [38].
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4.3 Specimen for glucose estimation
Glucose can be measured in whole blood, serum, or plasma, but plasma is
recommended for diagnosis. It can also be measured in capillary, venous or arterial
blood. It is essential that in a repeat sampling for confirmation of blood glucose
result, the same type of sampling used previously must be use. The molality of
glucose (i.e., amount of glucose per unit water mass) in whole blood and plasma is
identical. Although red blood cells are essentially freely permeable to glucose, the
concentration of water (kg/L) in plasma is 11% higher than that of whole blood
depending on the haematocrit, increasing to 15% at a haematocrit of 0.55 and
decreasing to 8% at a haematocrit of 0.30 [39]. Therefore, glucose concentrations in
plasma are 11% higher than whole blood if the hematocrit is normal. Glucose
concentrations in heparinized plasma are reported to be 5% lower than in serum
[40]. This may be caused by water shifting from red blood cells to plasma sequel to
effect of anticoagulants. In feed (OGTT) state capillary glucose is higher by about
[mean of 1.7 mmol/L (30 mg/dL), equivalent to 20–25%] than in venous blood, but
the mean difference in fasting samples is only 0.1 mmol/L (2 mg/dL) [41].
4.4 Fasting plasma glucose (FPG): a tool in screening for dysglycaemia
In 1997, ADA Expert Committee on the Diagnosis and Classification of Diabetes
Mellitus [42] recommended universal use of FPG for screening and diagnosis of
diabetes mellitus because of its ease of administration, convenience, acceptability to
patients, and lower cost in comparison to the OGTT and also based on assumption
that the measurement reproducibility would be better. Since the goal and premise of
diabetes management is the prevention of diabetes-associated complications, and
this goal is best achieved when the disease is diagnosed at an early stage, the
committee lowered the diagnostic threshold of FPG from 7.8 mmol/L to 7.0 mmol/L
and also created a new category, defined as individuals exhibiting FPG levels
between 6.1 and 6..9 mmol/L, called impaired fasting glucose (IFG) to describe the
zone between the upper limit of normal FPG and the lower limit of the diabetic
FPG. The IFG was believed at that time to be analogous to the zone between the
upper limit of a normal 2-hr plasma glucose and the lower limit of the diabetic 2-hr
plasma glucose described by IGT and was adapted by WHO in 1999 [43]. The FPG
of 6.1 mmol/L was adopted by both ADA [44] and WHO [43] as the upper limit of
“normoglycaemia” because this is the level above which first-phase of insulin
secretion is lost in response to intravenous glucose and is also the level at which
there is associated progressively greater risk of developing micro- and
macrovascular complications.
In 2003, the ADA reviewed its diagnostic criteria when it found out that the FPG
stated in the earlier classifications does not give corresponding hyperglycaemic
impact compared to the OGTT results. The threshold for IFG was lowered from
6.1 mmol/L to 5.6 mmol/L [44] dependent on ROC curve analysis indicating that a
cut-point of 5.4–5.5 mmol/L gives the best combination of sensitivity and specificity
for predicting future diabetes, and this consequently increased the overall preva-
lence of IFG approximately three- to four-fold, though WHO and IDF maintained
this as FPG 6.1–6.9 mmol/L. To date the searching to finding the corresponding FPG
to what is normal or IGT is still ongoing.
Although both IGT and IFG are associated with resistance to insulin and
increased insulin secretion, they do not identify identical patient populations and
are not equivalent in predicting development of T2DM or cardiovascular events
[45]. People with isolated IFG predominantly have hepatic insulin resistance and
normal muscle insulin sensitivity, whereas individuals with isolated IGT have
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normal to slightly reduced hepatic insulin sensitivity and moderate to severe muscle
insulin resistance [46]. Individuals with isolated IFG have reduction in both first-
phase (0–10 min) during IVGT and early phase (first 30 min) during OGTT insulin
secretion but maintained the late-phase (60–120 min) response during OGTT,
while Isolated IGT apart from having defect in early-phase insulin secretion in
response to OGTT also has a severe deficit in late-phase insulin secretion [47].
The prevalences of IFG and IGT varies widely, varied considerably among
different ethnic groups [48], differ significantly in their age and sex distribution;
and increase with advancing age. IGT is more frequent in women than in men [49].
A study of 1,245 Italian telephone company employees followed for 11.5 years found
that, unlike baseline IGT, baseline IFG did not predict progression to DM, and the
categories only overlapped 40% of the time [48]. The natural history of both IFG
and IGT is variable, with approx 25% progressing to diabetes, 50% remaining in
their abnormal glycaemic state, and 25% reverting to NGT over an observational
period of 3-5 years [50, 51].
4.5 Advantages of using FPG in screening for dysglycaemia
American Diabetes Associated did not recommend OGTT to be used commonly
in the diagnosis of type 1 and 2 diabetes because it was thought that if FPG is
appropriately use it will identify almost the same number of dysglycaemia in the
population as the OGTT, and that OGTT is not practicable in routine practice and in
many studies OGTT is found to be poorly reproducible, with an estimated rate of
only about 50–66% [52].
4.6 Disadvantages of FPG in screening for dysglycaemia
The fasting blood glucose testing in nondiabetic persons poorly identify early
signs of dysglycaemia because high postprandial glucose marks the journey of first
signs of abnormal glucose regulation and this best predict cardiovascular outcome.
Fasting is not really the central issue and it seems to be overemphasized in diagnos-
ing dysglycaemia.
One problem well known in the measurement of FPG in population studies is the
difficulty in ensuring that all the participants have complied with the instructions
about fasting [53]. Consequently, some participants with completely normal glucose
homeostasis might have been misclassified into impaired fasting glucose category
or, more rarely, even into a diabetes category. More so, FPG represents glucose
handling during the moment of fasting period only (particularly so, of that moment
of blood sampling), and this is affected easily by short-term lifestyle changes such
as over activity, stress and drug ingestions. Therefore under these conditions sub-
jects may be classified wrongly if only FPG is used. Knowledge of intraindividual
variability of FPG concentrations is essential for meaningful interpretation of
patient values. A study of healthy individuals [mean glucose, 4.9 mmol/L (88 mg/
dL)] exhibited within- and between-subject CVs of 4.8–6.1% and 7.5–7.8%, respec-
tively [34]. Recent evidence revealed a diurnal variation in FPG, with mean FPG
higher in the morning than in the afternoon, indicating that many cases of
undiagnosed diabetes would have been missed in patients seen in the afternoon
[54]. A study with repeated OGTT in 31 nondiabetic adults at 48-hr intervals,
demonstrated FPG varied by 10% in 22 participants (77%) and by 20% in 30
participants (97%) [44]. Similarly, in population studies of subjects with newly
diagnosed diabetes showed a wide distribution of FPG, ranging in one study from
<5.0 mmol/1 to >30.0 mmol/L [55]. As a consequence, the sensitivity of the OGTT
is naturally higher, given the current criteria.
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The change in the diagnostic procedure has brought a complex and variable effect
on the prevalence of diabetes and on subjects diagnosed. Many studies have reported
that FPG and 2-hr plasma glucose do not identify the same people as having diabetes.
The difference between the prevalence of diabetes based on the FPG and 2-hr criteria
varied from4.0% to 13.2% in the 16 European survey in the DECODE study. In that
study [56], of the 1517 people with newly diagnosed diabetes, 40% met only the FPG
criterion, 31%met only the 2-hr criterion and 29%met both criteria. In the DECODA
study [49], of 1215 subjects with diabetes by either criterion, only 449 (37%) met
both criteria, of the 995 subjects with 2-hr ≥11.1 mmol/L, 546 (55%) had non-diabetes
FPG value, and of the 669 subjects with FPG ≥7.0 mmol/L, 220 (33%) had non-
diabetes 2-hr value. In the two studies the concordance rate ranges between 29–37%.
In the NHANES study data cited in the 1997 ADA report showed 38% of subjects with
newly diagnosed diabetes using only ADA criteria were missed when OGTT was
carried out in the same population [42]. An even larger discrepancy was observed for
the categories of IFG and IGT. In DECODA study, more than three quarter (≥3/4) of
the subjects with IGT would be classified as normal if only the FPG criteria is used.
Degree of hyperglycaemia, age, sex, BMI and ethnicity influence the concordance.
The severer the hyperglycaemia the better the agreement between the two criteria. It
might therefore be appropriate to use the FPG alone in subjects with clinical symp-
toms of diabetes to confirm. It is inappropriate to use it as the only test in the general
population for epidemiological purposes, or in cohort with slightly higher glycaemia
but without any symptoms because a large proportion of subjects diagnosed by 2-hr
criteria would not be identified by the FPG particularly in Asians. In 1999, WHO
recommended retaining the use of OGTT for epidemiological purposes, and this
appears to be particularly important for the Asian population. The 2-hr criterion is
more sensitive in the elderly and fasting criterion in the mid-aged. Barrett-Conner,
et al. [57] reported that 70% of women and 48% of men aged 50–89 years had new
diabetes diagnosed solely by elevated 2-hr plasma glucose. Similarly, in the Early
Diabetes Intervention Program study [58], 24% and 50% of subjects with OGTT-
confirmed diabetes had FPG levels between 5.5 and 6.0 and 6.1–6.9 mmol/L, respec-
tively. Still in a further study, an isolated elevation of 2-hr glucose (2-hr glucose
≥11.1 mmol/L and FPG <7.0 mmol/L) identified as high as 65%(61/94) of those with
newly diagnosed diabetes while 76%(644/845) who were normal by fasting blood
glucose were identified with IGT and these individuals carry high risk of cardiovas-
cular disease events [59]. A recent report showed that even if the concordance
between the WHO and ADA criteria increased with this lower cutoff of IFG, 29% of
patients with diabetes revealed by an OGTT and 57% with IGT would still have
remained undiagnosed using FPG [59]. All individuals with IFG should have an
OGTT, as a significant number (approximately 5%, but up to 20%, in some
populations) will already have diabetes by 2-hr post challenge criteria [60], so why
delaying diagnosis, why not start with OGTT in the first place.
Impaired glucose tolerance (IGT), not diagnosed with FPG estimation, is asso-
ciated with risk of cardiovascular events almost as high as in subjects with diabetes
which is not similarly observed in people with IFG necessitating ADA to lowered
the threshold for IFG from 6.1 mmol/L to 5.6 mmol/L in order to detect more
subjects with pre-diabetes [61]. Consequently, with regards to the assessment of the
risk of mortality and cardiovascular disease events, these discrepancies are crucially
important. Therefore, in screening programs, clinical research, and population-
based epidemiological studies, where participants often lack diabetes symptoms or
complications, an OGTT is commonly used to detect diabetes, thus adding to the
diabetic “pool” an equal-sized group of subjects with unrecognized diabetes and it is
misleading trying to assess glucose homeostasis without information on
post-prandial glucose metabolism.
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In conclusion, although in clinical practice the OGTT is often regarded as a
cumbersome, time-consuming, and patient-unfriendly procedure, for a more
detailed and sensitive assessment of the glucose dysmetabolism, the oral glucose
tolerance test (OGTT) is the best.
5. Oral glucose tolerance test (OGTT): undeniably the best choice
investigation for dysglycaemia
The OGTT is a non-physiological procedure required to unveil a highly com-
pensated derangement in insulin’s handling of glucose metabolism [62]. It requires
administration of glucose solution to a patient who has indication for investigation
of glucose dysmetabolism. Although more sensitive diagnostic test than FPG, the
OGTT is affected by a number of factors that result in less acceptable reproducibil-
ity. Therefore OGTT requires that any influence in glucose handling must be elim-
inated or minimize where result should reflect patient’s internal milieu, to increase
reproducibility. Subsequently, patient preparation, a forvarable atmosphere during
the procedure, standardized sampling protocol, sample handling, and analysis are
paramount. OGTT or 2-hr post-glucose levels do indicates the pathophysiology
responsible for diabetes better than any other glycaemic parameter as it provides
information on what happens in the postprandial state, when glucose is high in the
system and when the functional capacity of pancreatic β-cell is crucial. Normal
blood glucose levels 2-hr after glucose load indicates a good β-cell capacity, whereas
high levels document an impairment of β-cell function [63]. This means that only 2-
hr OGTT PG can provide reliable information on the key pathophysiological defect
of dysglycaemia or providing advice regarding the correct therapy to overcome it.
5.1 Advantages of OGTT in screening for dysglycaemia
The oral glucose tolerance test has a long history [64] but from time to time had
to endure considerable criticism. One review pointed out that the considerable
number of variables involved results in both poor reproducibility and difficulties in
interpretation [65]. In spite of this the oral glucose tolerance test survives and for
routine use in the diagnosis of diabetes mellitus it is not replaceable (Undeniably).
The OGTT detects changes in post-prandial glycaemia that tend to precede changes
in fasting glucose. In fact, inability to respond appropriately to a glucose challenge,
i.e., glucose intolerance, represents the fundamental pathologic defect in diabetes
mellitus and OGTT is currently the gold standard for the diagnosis of diabetes. The
OGTT is vital for the characterization of metabolic syndrome, the metabolic actions
of cardiovascular and metabolic drugs, and natural progression from prediabetes to
T2DM. OGTT is extensively used as a sensitive indicator of GDM. Therefore, OGTT
is an important Lab tool in preclinical studies as it provides an indication of the
relative roles of insulin secretion and insulin resistance in the progression of glucose
intolerance.
The OGTT allows all of the normal stages of insulin secretion and glucose
processing to take place in sequence without causing stress or trauma to the subject.
The OGTT is the most robust means of establishing the diagnosis of diabetes and
provides a more comprehensive assessment of dynamic glucose handling. Thus, the
OGTT more accurately mirrors daily life. OGTT is much more sensitive in identi-
fying the loci of insulin resistance and its modulation by different interventions.
Thus, the OGTT is useful as a research tool, yields laboratory data with greater
relevance to the prevention and treatment of human disease. It is the reference
method for the assessment of glucose tolerance, despite the notoriously poor
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reproducibility of the test (CV = 50%) for 2 h blood glucose. Some of these cause of
variations can be minimized with adequate attention to physical activities, dietary
preparation and taking care of sample collection at the 2-hr sample (sampling must
be done within 5 minutes of 120 minute [66]. The WHO (1999) placed emphasis on
the OGTT as the “gold standard”, with both fasting and 120-min values being taken
into consideration [67]. This is by no means a mistake. Only when an OGTT cannot
be performed should the diagnosis rely on fasting levels. Other hormones and
metabolites can be measured during OGTT, not just glucose and insulin, eg., the
OGTT is the primary test used for the diagnosis of GH hypersecretion.
OGTT is the only means of identifying people with IGT, and IGT is an essential
diagnostic step, especially when FPG is within the normal range, as these subjects
are at high risk not only for type 2 diabetes, but in particular for cardiovascular
disease. The main clinical significance of IGT are [68]: (1) It is a risk factor for type
2 diabetes, about 20–50% of subjects with IGT develop type 2 diabetes over
10 years; (2) It predisposes individual to cardiovascular disease (CVD); and (3) It is
a component of the metabolic syndrome and its consequences. IGT when identified
and subsequently managed will prevent or delayed progression to type 2 diabetes
mellitus. It has been indicated by recent studies [69–71] that persons classified with
IGT using WHO criteria have increased risk of cardiovascular disease, however
many of these subjects do not have impaired fasting glucose (IFG) by the new ADA
criteria. Furthermore, the OGTT by WHO criteria identifies diabetes in 2% more
individuals than does FPG using ADA criteria [70], although diabetic individuals
who are identified by both abnormal FPG and 2-h OGTT have a higher risk of
premature death than those with only an increased FPG concentration [71]. More
so, fasting plasma glucose alone fails to diagnose in about 30% of cases of diabetes
diagnosed by OGTT. OGTT establishes whether an IFG subjects has normal 2hPG
and only the simultaneous information obtained from 2hPG (OGTT) allows the
screening to become effective. An important matter here is that people with IGT
who cannot be identified by either FPG or A1c have ≈40% increased mortality
compared with normoglycaemic subjects and lifestyle intervention in these indi-
viduals can prevents progression to type 2 diabetes and may reduce their mortality
risk to the level observed among normoglycaemic population. These prevention
benefits do not exist for A1c or FPG, and this evidences should not be forgotten
when deciding the approaches to identify intermediate dysglycaemia. We should
therefore make OGTT a priority in an attempt to diagnose hyperglycaemia as early
as possible.
Thus, using solely FPG, would deceitfully reassure a large proportion of indi-
viduals as having NGT, without warning them on the benefits of preventive treat-
ment. Epidemiological studies showed that A1c and plasma glucose (FPG and/or
2-hr OGTT) identify partially different groups of diabetic subjects. While A1c
≥6.5% identifies only ≈30–40% newly diagnosed patients with diabetes [72], a
larger percentage was detected by FPG (≈50%), and more so by 2-hr PG(≈90%).
These findings are based on several recent studies, including the 2003–2006
NHANES study demonstrating only 30% of diabetic individuals were detected by
A1c ≥6.5%, 46% by PFG ≥126 mg/dl, and the IRAS demonstrated 32%, 45%, and
87%, respectively) [73] indicating OGTT is superior. However, the pivotal issue on
OGTT is its low reproducibility which is significantly represented by physiologic
contexts of the test. The plasma glucose during OGTT are influenced by both
insulin sensitivity and secretion, however, impact of other factors particularly
incretins, neural responses to nutrient ingestion, gastrointestinal motility and
gastric emptying are also important. These factors differ significantly between
individuals and are part of non-modifiable factors that govern post-load glucose
metabolism and plasma glucose concentration, and are difficult to measure in every
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individual undergoing OGTT. Finally, all trials aimed at type 2 diabetes prevention
included IGT subjects [74, 75], who could not be possibly recognised without
OGTT, seems therefore evident that the routine execution of OGTT is presently the
one and only possible answer (Undeniably) [76].
5.2 Disadvantages of OGTT
5.2.1 Factors why OGTT may not be the first choose in screening for dysglycaemia
a. Biological variation which may account for about 5.7% of available blood
glucose value
b. Variable effects of administration of hyperosmolar glucose solution on gastric
emptying, eg, nausea, vomiting, osmotic diarrhea, abdominal distension.
Flavoring with sugar-free lemon and chilling increases palatability and may
reduce nausea.
c. More cost and time, Cumbersome, unfriendly procedure for patients
d. Because of the OGTT’s high variability and low sensitivity, epidemiological
studies based on a single OGTT may overestimate the prevalence of diabetes
by as much as 16%
Due to the number of limitations, the OGTT should be undertaken on two
separate occasions before the results are considered abnormal (unless the initial
results are grossly abnormal). It has high intra-and interperson variability. This may
be due to a number of factors, including diet and exercise during the days before the
test, caffeine use, smoking, medications, and stress. However, with careful patient
preparation the impact of these modifiable factors can be markedly reduced
resulting in improved reproducibility. These modifiable factors can be placed into
three categories:
a. When preparing patient for test: duration of fast; prior carbohydrate intake;
medications (e.g. thiazide, oral contraceptives and corticosteroids); trauma;
intercurrent illness; age; physical activity.
b. Glucose given: quantity of glucose ingested; volume of administration; and
rate of ingestion.
c. Fasting sample: posture; anxiety; caffeine; smoking; physical activity; stress,
and time of the day
This shows that with proper patient preparations spanning through history
taking and physical examination and appropriate patient education will highly
improve the reproducibility of OGTT, hence care must be taken of the factors
[65, 77] in Table 3 during patient preparation.
An increase in the volume or decrease in the osmolality of a meal may result in
an increase in the rate of gastric emptying and in a subsequent increase in
glycaemia. Gastric emptying has implications for the reproducibility of the OGTT.
It was twice observed that the faster an OGTT meal is emptied from the stomach,
the higher the resulting postprandial glycaemia level. About 30%, 19.8% and 14%
differences in postprandial glucose after the dilution of 75-g (present study), 50-g
and 25-g tolerance tests was noted, respectively [77]. The dilution effect is noted
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more between 90 and 180 minutes post-glucose solution ingestion. It is possible
therefore that some of the earlier reports of poor reproducibility of the test may be
attributable to a volume effect. The gastric emptying falls as the glucose concentra-
tion rises and this was demonstrated over a wide range of glucose concentrations
[77]. It has been suggested that this is due to the stimulation of receptors in the
duodenum sensitive to the osmotic pressure of the duodenal contents. The rate for
gastric emptying in normal individuals lies between 40 and 80 minutes. Chronic
pancreatitis does, however, causes overt diabetes in some patients, and most
patients with this condition have impaired insulin secretion [78] even if this is not
sufficiently severe to produce disturbances in carbohydrate tolerance. The liver,
situated between the portal and systemic circulation, is in a position to influence
oral glucose tolerance profoundly. Reproducibility can be improved by drawing
Blood at the stipulated time or at least within 5 minutes and centrifuge sample
within 45 minutes of drawing it to obtain plasma.
To improve the reliability of a test it should be conducted in the individual that
appropriately require the test, hence OGTT reproducibility can be improved when
it is conducted in the selected individuals noted in Table 4.
5.2.2 Patient’s preparation for conduct of OGTT, improving reproducibility
Interaction with patients before procedure is very important because one of the
conditions leading to spurious result in patient investigation is lack of patient’s
a. The OGTT is a non-physiological procedure
and the interperson variability is rather high.
b. Analytical and biological variability
c. Use of different samples(eg; venous and
capillary for a repeat or during same
procedure
d. Biological variation is been found to be up to
20–35%—these can be minimized by
stringent careful attention to the protocol
e. Other factors are: Lack of adequate patient
preparations, Diet
f. Exercise during the days before the test
g. Caffeine use, Smoking, Medications, Stress
h. Changed in ambient temperature
i. Volume of the glucose solution
j. Others are: gastric emptying, Intestinal absorption,
the gastrointestinal hormonal stimulus to insulin
release, the liver, and the pancreatic islets.
Table 3.
Causes of variability in OGTT results.
1. Age > 45 yrs. (type 2 among 40-70 yr
—7%, IGT—20%. In general pop—
4.3%
2. Body Mass Index(BMI) >27 kg/m2
3. High risk ethnic groups—Africans,
Carribeans, Asians
4. Family history(first-degree relatives
(increase risk by 2–4 fold
5. High waist circumference(>92 cm,
>80 cm)
6. Sedentary lifestyle
7. History of gestational diabetes mellitus
8. Previous evidence of IGT or IFG
9. Dyslipidaemia(decrease HDL and
increase TGs)
10. Patient with Cardiovascular disease
11. Women with polycystic ovarian disease
12. Woman who delivered a macrosomic baby(>4 kg)




16. It also helps determine if there is other condition that
affects blood glucose levels (e.g., Cushing’s syndrome,
celiac disease, cystic fibrosis, acromegaly,
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education and preparation. Interacting with patient is important in improving
reproducibility of test for the following reasons:
a. Enable the caregiver know about the patient—classify patient according to
the three categories of tests mentioned earlier
b. Educate patient about why he/she is coming for the tests, and emphasize on
what to avoid during pre-test period, and make patient to understand his/her
role in obtaining good result
c. Know types of medications patient is on and withdraw those possible and
record those which cannot be withdrawn
d. Emphasize the importance of patient’s compliance and the result outcome
e. This interaction will prepare patient’s mind and will alleviate fears and stress
6. Instructions to patient before the procedure: improving
reproducibility
The OGTT results can be affected by carbohydrate intake and duration
of fasting preceding the test, time of day for the test to be performed or
activity during the test, sample collection, and medications. Instructions are as
follows:
1.Patient must be on meal containing >150 g carbohydrate (approximately
ten 40 g slices of bread per day) in the last three days before the test, and
in the night before the test should take 30-50 g of carbohydrate containing
meal
2.No strenuous exercise three days prior to test, but normal work is allowed.
Patient should not rush when coming for the test (avoid stress). Need to rest
before for minimum of 15 minutes before conducting test
3.No alcohol or Caffeine use 48 hrs before the test and during the test
4.Overnight fast (8-14 hr) water is allow—for patients convenience
5.Time for the test (morning hour is preferred, convenience of overnight
fast, and fluctuation in FPG-higher in the morning and lower in the
evening)
6.Maximum 75 g, anhydrous (82 g monohydrate) glucose dissolved in
250–300 ml of water
7.Glucose solution ingestion within the shortest possible time—usually within
5 minutes. Intolerance for sweet taste—patient may come with lemon juice,
sometimes lucozide (375 ml) can be used instead.
8.Others are Glucola (224 ml) equivalent of 75 g anhydrous glucose. Polycal
liquid (previously called Fortical) is used as the glucose load. 61.4 g
maltodextrin/100 ml. Oral glucose solutions come in 10 US fluid ounces
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(296 ml) bottles containing 50, 75, or 100 g of glucose (5, 7.5, and 10 g per
fluid ounce)
9.If patient is under unavoidable stress, the test should be postponed
10.Patient should be aware of being seated in waiting area for a minimum of
2 hrs for the test
11.Failure to comply with all instructions will invalidate result
Ensure that all staff involved in undertaking any elements of the test have been
provided with suitable training and are assessed to be competent (Table 5).
7. Interpreting OGTT result: improving reproducibility
7.1 Considerations when interpreting OGTT result
When interpreting the result remember that OGTT has variable reproducibility
and care should be taken not to over-interpret the results. Use only one criterion, eg
WHO criteria, to indicate a diagnosis of IFG, IGT or diabetes. In most cases the
results of fasting and 2-hr post-glucose load are enough. Always look for help from
local diabetes serves in uncertainty. Refer cases you can not evaluate to endocrinol-
ogist for further for assessment. Usually there are no causes of false-positive result
when processes are strictly followed. These arts will improve the reproducibility.
7.2 While interpreting OGTT result you will not get information concerning
a. Patient preparation for and how the glucose was administrated.
a. Once patient arrived, confirm compliance with preparations, with emphasis on duration of
fasting
b. You may wish to put in place an indwelling drip for sampling to avoid the stress of repeated
needle pricking during sampling
c. Ensure patient is comfortable before starting the procedure
d. Take sample for fasting and any other investigations intended, before ingestion of glucose
solution
e. Constitute the glucose solution—75 g(anhydrous) and 82 g(monohydrous)—10% more of
anhydrous glucose, in 250–300 ml
f. Ask the patient to take the solution within 5 minutes
g. Time 0 minute of the test is when patient start taking the glucose solution and not when fasting
sample is taken
h. Take samples at 30 minutes interval for 2 hr.(3, 5 hrs) or at 2 hr. only
i. Same type of sample must be taken throughout the procedure(, venous or capillary)
j. No smoking, caffeine, alcohol or any exercise during the waiting period
k. Monitor patient especially when approaches convenience—patient may vomit
l. Should the patient sit, lie, stand, walk, talk, etc.(seating is preferred—minimal activity)
m. Only minimal activity is allow but ensue that patient remain comfortable throughout the
period of the test
n. Label samples appropriately, place sample ice-water slurry and ensure separation within
30 min of sampling
Table 5.
Conduct of OGTT in a non-pregnant adult.
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b. The result shows assessment of glucose tolerance at the time of the test only
and cannot provide any other information.
c. Results give only a qualitative idea of the average 24-hr blood glucose
d. Nor will result predict response to hypoglycaemic therapy or the current or
future risk of diabetes complications
Therefore result will be better interpreted with the cognition of the above in
mind.
7.3 Result interpretation
a. Normal response has the following characteristics:
1. Initial fasting glucose within normal limits
2.The highest value does not exceed the renal threshold (160-180 mg/dl
(8.8-10 mmol/L))
3.The fasting level is again reached by 2–2.30 hours
4.No glucose or ketone bodies are detected in any urine specimen
b. Response of diabetic patient
1.Fasting blood glucose may raise above normal usually in the impaired
range
2.The peak is reached between 1 and 1.30 hours
3.Glucosuria is usually present because the highest value exceeds the renal
threshold
4.Plasma glucose does not return to fasting level within 2.30 hours, the
most characteristic feature of DM response
c. LAG curve for oxyhyperglycaemia
1.Normal Fasting glucose level
2.Plasma glucose rises rapidly within 30 minutes to 1-hr post glucose
ingestion exceeds renal threshold with corresponding glucosuria
3.Return to normal quickly and completely
4.This is usually noted in Hyperthyroidism, post gastroenterostomy,
during pregnancy, early diabetes
d. Response for renal glycosuria
1.Glucose appears in the urine at normal plasma glucose much below renal
threshold
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2.Usually no glucosuria during fasting but mainly post-prandial
3.It may be physiological, in pregnancy or in renal disease or early
diabetes
e. A flat glucose tolerance curve can be a normal finding and is as a result of
rapid metabolism and not of either deficient absorption or slow gastric
emptying.
Under certain pathological conditions such as hyper- and hypothyroidism changes
in the gastric emptying rate may significantly alter the shape of the glucose tolerance
curves [79]. Rapid gastric emptying associated with duodenal ulcer and partial gas-
trectomy where plasma glucose rises rapidly within 30 minutes of glucose ingestion
stimulating hyperinsulinaemia and resultant reactive hypoglycaemia though mea-
surement of serum insulin levels does not reveal evidence of such direct relationship.
In a healthy young adult with increase physiologic activities, there is associated
rapid metabolism and when venous rather than capillary blood is analyzed, a flat
curve can be a normal findings and not of either deficient absorption or slow gastric
emptying. Hypoglycaemia in a fasting subject is normally prevented by hepatic
gluconeogenesis. This stopped after glucose ingestion when blood glucose rises, and
begun when plasma glucose is falling preventing fasting hypoglycaemia Reactive
hypoglycaemia in either normal healthy young adult, patient with peptic ulcer or
partial gastrectomy might, therefore, be due to the failure of the liver to resume
glucose production sufficiently and rapidly. The normal exponential pattern of
gastric emptying results in a very gradual decline of the rate at which glucose enters
the intestine and this should provide ideal conditions for the liver gradually to
resume glucose production. The absorption of glucose by the small intestine is
highly efficient. After ingestion of a concentrated solution, a combination of slow
gastric emptying, dilution within the duodenum, and active peristalsis ensure that
within the jejunum the glucose solution no longer remains hypertonic. The small
intestine is efficient in glucose absorption.
Every dynamic test requiring appropriate patient preparation and procedure for
the conduct of the test will not be without contraindication if result is to be reliable.
Such contraindications for conduct of OGTT are shown in Table 6. The primary
objective is to demonstrate presence of dysglycaemia in a condition that has long
latent period, except when monitoring success of treatment in secondary causes of
hyperglycaemia. Subject must be conscious and alert to obey order (in both prepa-
ration and conduct of the test), in a no stressful condition, physically or otherwise.
Patient should be able to take the stated amount or an equivalent and under
influence of no other condition except what is being investigated for.
a. Diagnosed diabetes mellitus
b. Suspected Type 1 DM
c. Unconscious patient
d. Patient who can not obey instructions
e. Refusal to follow instructions
f. Not for diabetes follow-up except during
treatment of secondary diabetes; eg
acromegaly, glucagonoma, Cushing’s
syndrome, Phaeochromocytoma
g. Hospitalized, acutely ill or immobile patients
h. Vomiting during the procedure
i Patient who could not consumed the glucose
solution
j. Patient who developed moderate to severe
hypoglycaemia during the test
k. Do not perform the test on patients with
uncontrolled thyroid dysfunction, under
physical stress, eg post surgery, trauma,
infection or extreme psychological stress or in
patient with hypokalaemic periodic paralysis
Table 6.
Conditions under which OGTT should not be conducted or when procedure should be stopped.
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7.4 Testing of children for type 2 diabetes mellitus
Until recently, type 1 diabetes was the most frequent form of diabetes among
young people [80]. Recently however, there are increasing reports of T2DM, previ-
ously a disorder of middle-aged or elderly persons among children and adolescents.
In the 1990s, various reports indicated that the incidence of childhood type 2
diabetes was increasing and this trend continues at present. The ADA and the
American Academic of Paediatrics approved screening for T2DM in children
because T2DM can be asymptomatic at diagnosis and requires tight glycaemic
control to delay the onset of chronic vascular complications. Several studies have
shown an increased risk of microvascular complications among young adolescents
with T2DM compared to those with T1DM. Therefore, screening for IGT and T2DM
in children at risk of glucose intolerance is necessary.
7.4.1 Criteria/indications
a. Overweight (BMI ≥ 85th percentile for age and sex, weight for height ≥ 85th
percentile, or weight >120% of ideal for height)
1.Plus any two of the following risk factors
2.Family history of Type 2 DM, 1o or 2o
3.Native American, black, Asian, Latino
b. Signs of insulin resistance (acanthosis nigricans, hypertension,
dyslipidaemia)
c. Age of initiation: 10 years or onset of puberty
d. Frequency: every two years
e. Test: FPG preferred
The dose of glucose is weight dependent-1.75 g/kg body weight. The maximum
load is 75 g. Lucozade may be given instead which is more palatable. Formulation
73 kcal carbohydrate/100 ml, gives 75 g glucose in 419 ml Maximum dose is 75 g.
Apply ametop gel 45 minutes prior to cannulations to ensure the area is numbed.
Utilize a member of the play team to prepare the child for the procedure and
provide distractive techniques throughout. Give full explanations to the child and
family about the procedure and answer any questions they may ask.
8. OGTT in gestation diabetes mellitus, an undeniably the only test for
dysglycaemia of GDM
8.1 Gestational Diabetes Mellitus (GDM)
Normal pregnancy is characterized by approximately 50% decrease in insulin-
mediated glucose disposal in humans and a 200–250% increase in insulin secretion
to maintain euglycaemia in the mother [81]. Women with adequate insulin secret-
ing capacity overcome this insulin resistance of pregnancy by secreting more
endogenous insulin to maintain normal blood glucose. In a study involving
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non-GDM pregnancies, plasma glucose levels during late pregnancy (mean  1 SD)
were noted to be fasting 3.9  0.4 mmol/L, 1 hour postprandial 6.1  0.7 mmol/L,
and 2 hours postprandial 5.5  0.6 mmol/L with a mean glucose of 4.9  0.6 mmol/
L [82]. The HAPO study reported a mean fasting glucose of 4.5  0.4 mmol/L,
derived from 23316 pregnant women [38]. But women with diabetes or those who
have tendency to develop GDM, endogenous insulin secretion is inadequate to
compensate for the insulin resistance (IR), hence their hyperglycaemia worsen or
they development hyperglycaemia.
Numerous factors such as placental hormones, obesity, inactivity, an unhealthy
diet, genetic and epigenetic contributions influence IR in pregnancy, but the causal
mechanisms are complex and still not completely elucidated [83]. Placental derived
hormones are believed to be a major factor in reprogramming maternal physiology
to achieve an I-R state. Human placental lactogen (hPL) and human placental
growth hormone (hPGH) are the major player in pregnancy induced IR [84].
Prolactin, progesterone, estradiol and cortisol are increased during pregnancy and
may contribute to the development of IR in pregnancy [85]. Recently, studies have
implicated adiponectin from adipocytes and secreted factors, such as TNF-α, leptin,
IL-6, resistin in mediating IR of pregnancy [86]. Most women who develop GDM
have increased IR caused by alteration in insulin signaling pathway, abnormal
subcellular localization of GLUT4 transporters, increased expression of the mem-
brane glycoprotein PC-1 or reduced insulin-mediated glucose transport. GDM is
usually diagnosed after 20 weeks’ gestation when placental hormones are increase
substantially as the placental size increases.
In 2014, the WHO has defined hyperglycaemia in pregnancy (HIP) as diabetes
first detected at any time during pregnancy, along with pre-existing diabetes and is
further sub-classified as diabetes in pregnancy (DIP) and gestational diabetes
mellitus (GDM) [87]. Nowadays type 2 diabetes is frequently found in young
women due to ongoing epidemics of obesity therefore the number of undiagnosed
(before pregnancy) is increasing. Screening for GDM earlier than 24-28 weeks in
identifying these young women and address perinatal risks that may be particular to
their greater degree of hyperglycaemia is becoming more important because of the
following [87]:
1.Rise chances of congenital malformations in offsprings
2.Risk of diabetes complications requiring treatment during early part
pregnancy
3.Early treatment Prompt or frequent follow-up to maintain normoglycaemia
4.Post-pregnancy screening ensuring confirmation and appropriate treatment of
diabetes after pregnancy
How then do we identify these women? Early glucose testing is important.
Usually in early part of pregnancy (e.g. first trimester and first half of second
trimester) fasting and postprandial glucose concentrations are normally lower than
in normal due to less effect of placental hormone and decreased appetite, compared
to non–diabetes women. Elevated fasting or postprandial plasma glucose levels at
this time in pregnancy may reflect diabetes antedating pregnancy. In this regards
there was a uniform agreement during IADPSG Pasadena meeting that this assess-
ment should be made during the initial visit for prenatal care. However, there is
variability in time of enrollment for prenatal care beyond the control of health care
providers. Accordingly, no limit can be place on the timing of initial assessment for
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detection of overt diabetes in pregnancy. It was advised that selective, stepwise
screening particularly in the low- and mid-income countries is more cost effective.
This entail: (a) Categorizing all women at first antenatal visit into low, moderate
and high risk of GDM; (b) Those in moderate to high risk groups should have
glucose challenge test with 50 g anhydrous glucose diluted in 150 ml of water to
drink and venous sample is taken at 1-hr. If result is 7.8 (7.2) mmol/L, at first visit,
proceed to diagnostic OGTT. If result is negative repeat glucose challenge test at
24–28 weeks of gestation; (c) Those in low risk group should be screening only at
24–28 weeks of gestation. However, if enrollment is at 24 weeks gestation or later
and overt diabetes is not found, the initial test should be either 50 g glucose
challenge first or the 75-g OGTT. Although IAFPSG Consensus Panel members
favored use of A1c at first visit, this is not feasible in most low- and mid-income
countries. It was also recommended that an FPG value in early pregnancy
≥5.1 mmol/L (92 mg/dl) also be classified as GDM.
Determining prevalence of GDM is difficult due to inconsistencies in screening
methods. Because the IADPSG’s is stricter when applied by IDF about 14% of 18
million live births were affected by gestational diabetes mellitus, where South-East
Asia had the highest prevalence of GDM at 24.2% and the lowest was in Africa at
10.5% [88]. Almost 90% of cases of hyperglycaemia in pregnancy occurred in low-
and middle-income countries, where access to maternal healthcare is limited. In
Nigeria, the prevalence of HIP is projected to be 13.9%, and age-adjusted prevalence
of 37.5% (crude 41.0%) in the United Arab Emirates is note [89]. The incidence of
GDM has increased over the past decades in parallel with the increase in rates of
obesity and type 2 diabetes mellitus, and this trend is expected to continue. GDM
affects 7% of all pregnancies worldwide, 1.1% to 14.3% in USA, 3.8% to 6.5% in
Canada, 6–9% in India. It is diagnosed at 16.3% in ≤16 weeks of gestation, 22.4%
between 17 and 23 weeks and 61.3% after 23 weeks of gestation [90]. It occurs more
frequently among African Americans, Hispanic/Latino Americans, and American
Indians. It is also more common among obese women and women with a family
history of diabetes. After delivery, GDM will follow 1 of 3 clinical courses [91, 92]:
a. Approximately 10% continue to have markedly abnormal glucose metabolism
and fulfill criteria for diabetes in the nonpregnant adult these patients are
reclassified as having diabetes (Hyperglycaemia in pregnancy).
b. Approximately 5–10% of patients continue to exhibit abnormal glucose
metabolism that is below diabetic levels. These patients are reclassified as
having IFG or IGT, as appropriate.
c. The remainder exhibit normal glucose metabolism.
GDM has about 20–50% chance of developing type 2 diabetes in about 5–
10 years even when there is lack of signs and symptoms of diabetes. The enormity
defers among different ethnic groups, ranging from 9% in Caucasians, 11.9% in
Latinos, and 25% in women of Mediterranean or east-Asian descent [93]. When
GDM women were followed for a longer period, higher incidence of type 2 diabetes
after index pregnancies was noted in 40% while there are evidence rates as high as
70% in Canadian Aboriginal women [93].
8.2 Should we then screen for GDM
Screening and diagnosis of GDM and treating it effectively not only prevent
adverse maternal and perinatal outcome but also future diabetes in both mother
22
Type 2 Diabetes - From Pathophysiology to Cyber Systems
and child. The goal of screening therefore is to reduce maternal and fetal compli-
cations such as preeclampsia, caesarean delivery, congenital malformations,
macrosomia, shoulder dystocia, nerve palsy, bone fracture, hyperbilirubinaemia
and infant death, or later childhood/adolescent overweight as demonstrated in
some studies. The Australian Carbohydrate Intolerance Study in Pregnant Women
(ACHOIS) [94], showed a 4% reduction in the composite outcome of severe
perinatal complications (death, shoulder dystocia, bone fracture, nerve palsy)
among women randomized to routine care compared with 1% among the inter-
vention group, while in the National Institute of Child Health and Human Devel-
opment (NICHD) study, though there was no reduction in the composite primary
outcome (perinatal mortality, birth trauma and neonatal hypoglycaemia,
hyperbilirubinaemia, or hyperinsulinaemia), there was reductions in fetal over-
growth, shoulder dystocia, caesarean section delivery and pre-eclampsia. During
pregnancy, gestational diabetes requires treatment to normalize maternal blood
glucose levels to avoid complications in both the infant and the mother. Untreated
hyperglycaemia in pregnancy may result into either or all of the following com-
plications in Table 7.
About 10–25% of infants born of GDM pregnancies are macrosomic; maternal
euglycaemia in labour reduces the risk of hypoglycaemia, hypocalcaemia,
hyperbilirubinaemia and polycythemia in the baby. In addition, the maternal
metabolic milieu was identified as a key determinant for the susceptibility to
obesity, metabolic syndrome and T2DM in the offspring, a phenomenon often
described as ‘fetal programming’. A study showed that infant of GDM were
followed biennially from the age of 5 years using 75 g 2-hr OGTT among the Pima
Indians in Arizona, USA, and Diabetes developed in the next generation in 6.9%
and 30.1% of breast-fed offspring of non-diabetic and diabetic women, respec-
tively and in 11.9% and 43.6% of bottle-fed offspring, respectively. Shoulder
dystocia (SD) occurs in 1–2% of pregnancies, with majority of cases occurring in
non-macrosomic fetuses, however, it increased for all birth weights, with a three-
fold increase when birth weight is >4000 g. Brachial plexus injury (BPI) occurs
in 0.06%–0.26% of normal deliveries but occurs in 16–23% of births complicated
by shoulder dystocia. GDM is an independent risk factor for BPI with a relative
risk of 1.9–3.19 but in only 6–10%% of BPI is maternal GDM documented. It can
be inferred therefore that the incidence of adverse perinatal outcomes increases
as glucose intolerance increases, that identification of women with
hyperglycaemia in pregnancy has clinical significance. As hyperglycaemia in




c. Shoulder dystocia and Brachial plexus injury
d. Macrosomic baby (weight ≥ 4 kg) or weight of
>90th centile for gestational(according to
ethnicity)
e. Baby is prone to hypoglycaemia
f. Hyperbilirubinaemia
g. Increase tendency of assisted delivery,
Caesarean section, or induction of labour
a. Respiratory distress in the baby, and
associated feeding problems
b. Pregnancy induced hypertension,
Pre-eclampsia and eclampsia
c. The risk of developing diabetes later
in life or in a future pregnancy is
increased
d. Haemorrhage and preterm delivery
e. Sevenfold higher risk of the mother
developing T2DM after pregnancy
f. Increase chances of death in both
mother and the baby
Table 7.
Complications of GDM if it is not diagnosed or properly managed [95].
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8.3 What is the optimal method of screening for GDM?
a. The optimal method of screening for GDM depends on the location, the
strength of the health facility, the principle of practicing Physician and
affordability of the patients. Screening is therefore either universal based or
risk factor based [96].
b. In order to reduce the burden of screening on women and the health care
system, the concept of selective (risk factor based) screening was introduced.
c. The goal of risk factor based screening would be to ideally identify through
historical and clinical factors those patients who would benefit most from
biochemical screening while allowing those at lower risk to avoid the
screening processes. This is preferred particular in the low-income and mid-
income nations
d. Selective screening originally consisted of taking a personal and family
history in order to identify a high-risk population in need of further directed
testing. With this method, women are categorized into low-risk, moderate-
risk and high-risk. Women with any of the risk factors below were advised to
perform a 50 g glucose challenge test.
e. High risk women should undergo diagnostic test as early in pregnancy as
possible and that testing should be repeated at 24–28 weeks if initial results
are negative
f. Screening by risk factors alone has a sensitivity of 63% and a specificity of
56%. In other words, 37–50% of women with GDM may go undiagnosed
using this approach.
g. Hence universal screening was considered and is widely practices. Universal
screening for GDM is practiced by 84% of Canadian obstetricians, 94–97% of
US obstetricians; however in recent survey only 17% of physicians in the UK
practiced universal screening while 11% did not screen for GDM and 72%
screened in the presence of maternal risk factors.
Routine screening of women at 24–28 weeks of gestation may be recommended
with 50 g glucose challenge test (GCT), using a threshold of 7.8 mmol/L (140 mg/
dl), except in those who fulfill the criteria for low risk and may not need screening
for GDM at all. Properties used in categorizing a woman to at low-risk are [95, 96]
(Table 8).
Women at moderate risk: women who do not meet all low risk criteria but lack
two or more risk factors for GDM. Average-risk patients (all patients who fall
between low and high risk) should be tested at 24–28 weeks of gestation. High risk
a. Caucasian or member of other ethnic group with low prevalence of diabetes
b. Pregnancy with body mass index(BMI) ≤27 kg/m2
c. No previous history of GDM or glucose intolerance or adverse pregnancy outcome associated
with GDM
d. No family history of diabetes in first-degree relative
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criteria are: This category of women needs to be screened at first antenatal visit and
repeat at 24–28 week if they were negative at early screening. Women with these
features are categorized as high-risk [95, 96] (Table 9).
The most common method of screening is with stepwise 50 g OGTT at 24 to
28 weeks of gestation, followed by an OGTT as the diagnostic test if a certain
threshold has been surpassed. The procedure for glucose challenge test (GCT), is
that 50 g anhydrous glucose load dissolve in 150 ml fluid to be ingested within
5 minutes irrespective of time of the day or last meal. Blood is collected 1-hr post
ingestion of glucose solution Views diverge on the optimal cutoff value for the 50 g
GCT. 90% of women with GDM will be identified if 7.2 mmol/L (130 mg/dl) is used,
however, as high as 20–25% of those screened will to undergo 100 g OGTT for
diagnosis. Increasing the cutoff value to 7.8 mmol/L (140 mg/dl) will identify only
80% of women with GDM but decrease to 14–18% of women will do 100 g diagnostic
testing [97]. A cutoff value of 7.2 mmol/L is advice in those with FPG level is
<140 mg/dl (<7.8 mmol/L) and manifests symptoms compatible with complications
of diabetes. Finally, at 24 to 28 weeks of gestation, every women should undergo 50 g
challenge test and those with values between 7.2 to 7.8 mmol/L (130–140 mg/dl)
should proceed to 100 g OGTT for diagnosis of GDM and sampling over 3-hrs.
As women with negative GCT do not undergo the diagnostic OGTT, it is possible
that they could have undiagnosed GDM or GIGT. In a study involving 202 pregnant
women with a negative GCT screening test that underwent subsequent OGTT, the
only positive predictor noted is the average glucose value in those with normal and
those with GDM/GIGT. Therefore, false negative GCTs cannot be readily predicted
by risk factors. However, their clinical implications at delivery may be benign [98].
During pregnancy, some women have a low glucose level on the 75 g OGTT. These
women tend to have more booking weight and higher rate of congenital anomaly;
however their pregnancy outcome was shown not to be significantly different from
those with normal screening OGTT results [99]. The performance of the GCT as a
screening test depends on the cutoff values used, the criteria for diagnosis of GDM
and the prevalence of GDM in the screened population. A study conducted in China
where 422 gravidas [100] were screened with 50-g glucose and those with a positive
results (≥135 mg/dl (7.5 mmol/L)), underwent additional glucose testing. GDMwas
defined using National Diabetes Data Group (NDDG) standards for the 3-h GTT.
When Carpenter and Coustan was used for comparison, any woman with elevated
50-g value and no 3-hr OGTT was performed, a fasting serum glucose ≥140 mg/dl
(7.8 mmol/L) were considered evidence of gestational diabetes. One hundred
twenty four (29.4%) had GDM as defined by the NDDG criteria; this increased to
161 (38%) when the diagnosis was based on Carpenter and Coustan’s criteria. As
expected, the prevalence of GDM increased in relation to an increasing 50-g value.
All subjects with a 50-g screen >216 mg/dl (>12.0 mmol/L) had evidence of gesta-
tional diabetes and required insulin for glycemic control. Patients with a 50-g screen
≥220 mg/dl (12.2 mmol/L) do not require a 3-h GTT. Those with fasting serum
a. Obesity(BMI ≥ 30 kg/m2
b. Previous macrosomic baby weighing ≥4.5 kg
c. Previous GDM
d. Glucosuria(1+ on two occasion or 2+ on one occasion)
e. Family history of T2DM(first degree relative with T2DM)
f. Ethnic family origin with a high prevalence of DM
g. Clinical conditions associated with insulin resistance like PCOS, acanthosis nigricans
h. History of hypertension or hypercholesterolaemia
Table 9.
Feature indicators of women at high-risk for GDM.
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glucose of ≥140 mg/dl (7.8 mmol/L) may begin diet therapy, glucose monitoring,
and insulin as indicated. If the fasting serum glucose is <140 mg/dl (7.8 mmol/L), a
3-h GTT should be performed for confirmation of GDM. This approach will facili-
tate rapid therapeutic intervention and reduce the cost of care in this subset of
patients. This findings need to be validated at different places using different ethnic
groups. What should be considered an indication for screening for gestation
diabetes mellitus (GDM) (Table 10).
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of
women of reproductive-aged and is the most common endocrine-associated cause
of infertility. Approximately 6.5% of women of reproductive age have PCOS.
Women with PCOS are known to be at increased risk for IR, IGT, and type 2
diabetes mellitus though often present with normal FPG [102]. The current guide-
line of Androgen Excess Society is that a 2-hour OGTT be performed on all obese
women with PCOS [102]. Though screening for GDM is considered compulsory in
affluent countries and highly recommended in low- and middle-income countries,
the administering the required amount of glucose in pregnancy is not without side
effects. The recognised disadvantages are as noted in Table 11, ranging from mild to
moderate consequences.
However, advantage almost always surpasses the disadvantages. The advantages
are as shown in Table 12.
8.4 Diagnosis of GDM is only done using OGTT
The gold standard for the diagnosis of GDM is OGTT irrespective of how it is
performed, using 100 g as recommended by ACOG, or 75 g, according to the ADA
criteria.
In 1964, O’Sullivan and Mahan first developed the two-step method OGTT for
the diagnosis of GDM [103] and this is based on the risk of maternal type 2 diabetes
later in life [104]. As explained earlier, those with glucose levels meeting screening
limit undergo a 100 g, 3 hours or 75 g, 2-hour diagnostic OGTT and by Carpenter
and Coustan (C-C) criteria, GDM is diagnosed in women with two or more abnor-
mal values (5.3–10.0-8.6 mmol/L at fasting, 1-hr and 3-hour (2 hour) post glucose
[104]. This with some modifications was adapted by many organizations, NDDG
a. Previous pregnancy with gestational diabetes
b. Previous ‘big’ baby (at or over 4.5kgs – 10lbs)
c. Frequent loss of pregnancy or premature delivery
d. Large for gestational age
e. Positive glycosuria(1+ on 2 occasions or 2 + on one
occasion)
f. BMI ≥30 kg/m2
g. Maternal age ≥ 40 years old
h. A family history of diabetes (first degree
relatives)
i. A previous still-birth
j. Long usage of steroids
k. Women with PCOS (Polycystic ovary
syndrome)
l. Polyhydramnios
m. High risk ethnic groups
Table 10.
Indications for OGTT in pregnancy [101].
1.There are no serious direct risks to the GTT, however, some women reported dizziness, fainting,
vomiting, due to fasting and/or the use of a high glucose drink on an empty stomach
2.Fasting for 8–12 hrs in pregnancy can be difficult
3. Soreness, bruise, swelling or infection at site of needle insertion
4.More cost burden in a patient with positive or borderline result who has be closely monitor
5.Patient may not be eligible for midwifery led care options such as homebirth or MLU
6. Induction of delivery may be recommended before date is due
Table 11.
Disadvantages of the OGTT in a pregnant woman.
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[105], ADA [106], as the standard method for diagnosis of GDM for more than two
decades.
In 2008, the HAPO study [39] demonstrated presence of unfavourable neonatal
outcomes even in those with mild hyperglycaemia which did not meet the old
criteria of GDM [107]. Based on this notion the International Association of Diabe-
tes and Pregnancy Study Group (IADPSG) recommended a one-step 75 g OGTT
testing but lowered the diagnostic cut-point of the OGTT to (5.1–10.0-8.5 mmol/L,
fasting, 1-hour and 2 hours postprandial) in 2010 [108] and only one abnormal
value was enough to make a diagnosis. This was adopted by ADA [109], WHO
[110] and FIGO [111] by recommending a one-step 75 g glucose OGTT between 24
and 28 gestational weeks and diagnosis of GDM is made with only one abnormal
value equal to or exceeding 5.1–10.0-8.5 mmol/L, due to the result of the HAPO
study regarding mild hyperglycaemia and adverse clinical outcome, including LGA,
primary caesarean, clinical neonatal hypoglycaemia, and C-protein cord blood
[108] where a more strict strategy may help reduce the frequency of these potential
complications. However, several guidelines including the ACOG [112], NIH [113]
and SOGC [114] did not support the IADPSG criteria and their guidelines still
recommend the two-step strategy and the C-C or NDDG criteria for the OGTT, the
reasons provided are:
a. The benefit from the treatment of mild GDM in women is not well established
b. Additional healthcare costs will be generated by increased prevalence
c. Caesarean delivery and intensive newborn assessment will increase
d. Life disruptions and psychosocial burdens will be developed in a patients with
GDM
Current ADA guidelines recommended selective screening of high risk women
for GDM, where ACOG guideline advice universal screening and NICE guideline
recommended screening all women of South Asians ethnicity. In the HAPO study
risk of adverse outcomes were very low when FPG was ≤4.4 mmol/L (80 mg/dl). In
Chinese women with FPG value ≥5.1 mmol/L, one can make a diagnosis of GDM
(specificity 100% and, in those with value ≤4.4 mmol/L one can exclude GDM
(87.8%, sensitivity). These results are similar to those reported by Agarwal, et al. in
the HAPO cohort. In HAPO and two other studies, the incidence of selected adverse
maternal and fetal outcomes increases along a continuum of increasing maternal
hyperglycaemia, with no outcome-associated glycaemic thresholds were identified
that could be used to define internationally accepted criteria for the diagnosis of
GDM. In 2010, IADPSG [108] consensus panel using HAPO study primary
outcomes (birthweight >90%, primary caesarean section rate, neonatal
hypoglycaemia and cord C-peptide levels >90%) and threshold for 75-g OGTT
a. The GTT is considered the most effective way to determine if you have GDM
b. Early detection of GDM gives a better chance of monitoring glucose levels
c. Managing glucose levels early decreases the risks to the baby
d. Managing the glucose levels early decreases the chances of macrosomic baby and its
complications
e. Managing glucose levels decreases the risk of interventions in labour and delivery
Table 12.
Advantages of OGTT for a pregnant woman.
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reached odds ratio 1.75. These arbitrary thresholds, when applied to the HAPO
cohorts, led to a GDM incidence of 17.8%. In 2013 Canadian Diabetic Association
expert committee conceded the dispute and chosen sequential screening with a 50 g
GCT followed by 75 g OGTT using the glucose thresholds that result in an Odds
Ratio (OR) of 2.00 (fasting ≥5.3 mmol/L, 1 hour ≥10.6 mmol/L, 2 hours
≥9.0 mmol/L).
Hyperglycaemia first detected at any time during pregnancy should be classified
as either:
• Diabetes mellitus in pregnancy
• Gestational diabetes mellitus
When glucose abnormalities persist postpartum in a woman with GDM, her
diabetes is re-categorized as overt diabetes, especially if the diagnosis of GDM
occurred before 20 weeks’ gestation and glucose levels were markedly elevated in
pregnancy. The 2006WHO criteria should be used in diagnosis of Diabetes mellitus
in pregnancy when one or more of the following criteria are met:
• FPG ≥ 7.0 mmol/L (126 mg/dl), demonstrated on two occasions
• 2hPG ≥ 11.1 mmol/L (200 mg/dl) following a 75 g oral glucose load
• RPG ≥ 11.1 mmol/L (200 mg/dl) in presence of diabetic symptoms
The diagnosis of GDM at any time during pregnancy should be based on any one
of the following values:
• FPG 5.1–6.9 mmol/l (95–125 mg/dl)
• 1hPG 75 g OGTT ≥10.0 mmol/L (180 mg/dl)
• 2-hPG 75 g OGTT 8.5–11.0 mmol/L (153-199 mg/dl)
There are no established criteria for the diagnosis of diabetes based on the 1-hour
post-load value. At least one of these thresholds must be equaled or exceeded to
make a diagnosis of GDM.
9. A1c, Can it replace OGTT?
The measurement of A1c equals the assessment of hundreds (virtually
thousands) of fasting glucose levels and also capture postprandial glucose
peaks; therefore, it is a more and reliable measurement than FPG and/or
2-hr OGTT plasma glucose (PG) oscillates above and below the cut point of
200 mg/dl.
FPG of 6.7 mmol/L to 7.2 mmol/L (120 or 130 mg/dl) or having a 2-h PG of
10.3 mmol/L to 11.9 mmol/L (185 or 215 mg/dl) are considered similar because they
define a point where physiological disturbance is apparent, however from other
angles it makes a lot of difference. Therefore, an appliance evaluating chronic rather
than spot hyperglycaemia is unquestionably more desirable. A1c assay is now the
preferred test not only for chronic management of diabetes but also for its
diagnosis. However, the cost of assay in some parts of the world rules out its typical
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use. In such instances, clinicians should continue using glucose measurements for
both diagnosis and monitoring of diabetes.
A1c assay may not be reliable under the underlisted conditions [115]
a. First, some haemoglobin traits, such as HbS, HbC, HbF, and HbE, interfere
with some A1c assay method. These are common among blacks
b. Second, conditions causing changes in red cell turnover: haemolytic
anaemias, chronic malaria, major blood loss, or blood transfusions,
c. Third, A1c levels appear to increase with age [116], though this is not
sufficiently clear
d. Similarly, racial disparities in A1c, the etiology and significance are unclear
[117]
e. Finally, in rapidly evolving type 1 diabetes, no time to “catch-up” with the
sudden elevations in glucose levels; diagnosis should be relied on plasma
glucose in association with typical symptoms
The glycated haemoglobin (HbA1c) test has been suggested as an alternative
screening test for type 2 diabetes. HbA1c overcomes many of these difficulties as
fasting state is not required, analytical variability is less than 2% and gives
glycaemic status over past 2–3 month. The coefficient of variation is usually 2–3%
for the same day analysis, while the inter-assay variation is 4–5%. HbA1c values are
relatively stable after collection, and the recent introduction of a new reference
method to calibrate all HbA1c assay instruments should further improves HbA1c
assay standardization.
Advantages of HbA1c assay are:
a. better indicator of overall glycemic exposure
b. less variability, unaffected by outside factors like stress
c. not a timed test, requires no fasting; more convenient
d. Better at predicting complications
Regrettably, at variance with that report, the New Hoorn Study [118] showed
that 44% of people with newly diagnosed diabetes with OGTT had A1c < 6.0% and
that a stronger correlations between plasma glucose and A1c is better in subjects
with known diabetes, but not in the general population. Moreover, in the Rancho
Bernardo Study [119], 85% of the participants with A1c ≥6.5% were not classified as
diabetes by ADA criteria and a 1/3rd of people with diabetes on OGTT had A1c
1.Assay is normalized and aligned to the DCCT/UKPDS
2.Better summary of overall glycaemic exposure and risk for long-term complications
3. It has significantly less biologic fluctuation
4.No need for fasting or timed samples
5.Relatively unaffected by acute(eg stress or illness related) perturbations in glucose levels
6.Currently used to guide management and adjust therapy
Table 13.
The beauty of A1c testing compared to blood glucose for diagnose of diabetes mellitus.
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< 6.0%. Thus, this study demonstrated that 30% of subjects who are already
diabetic or pre-diabetic would have been missed if A1c had been used instead of
OGTT. In conclusion, the data confirmed, in agreement with an Australian study,
that an A1C ≤5.5% or ≥ 7% can predict the absence or presence of diabetes
respectively, while intermediate values are inconclusive (Table 13).
A1C values just above the upper limits of normal, depend upon post-prandial
glycaemias (ie 2hPG), still requiring the OGTT to be correctly interpreted.
Although in certain cases A1c gives equal or almost equal sensitivity and specificity
to glucose measurement, it is not available in many part of the world and it is not
well enough standardised for its use to be recommended at this time particularly in
low- and mid-income countries.
Finally, although ADA recommended the use of A1c, by emphasizing the
importance of IFG and IGT, which cannot be diagnosed without OGTT, to disclose
high-risk subjects for diabetes, obviously shows that A1c would be of minute use
without OGTT and that pre-diabetes includes different entities. OGTT is the only
test that can efficiently disclose obscure diabetes when FPG<7.0 mmol/L and
screen competently within the range of rather heterogeneous pre-diabetic
values [120].
In conclusion an OGTT is undeniably the best test in investigation of
dysglycaemia, either with the intention of testing for pre-diabetes, type 2 diabetes,
or for gestational diabetes mellitus.
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